In brief
Iga Swiatek, the five-time Grand Slam champion, has accepted a one-month suspension due to a positive doping test for a heart medication from a contaminated product. The International Tennis Integrity Agency validated her claim of no significant fault, leading to a reduced ban.
Iga Swiatek, ranked as the world's number two and a prominent figure in women’s tennis, has accepted a one-month doping suspension after a positive test for trimetazidine (TMZ), a banned heart medication. The 23-year-old, who has claimed the French Open title five times, was tested out of competition in August 2024 when she held the number one rank. The International Tennis Integrity Agency (ITIA) announced that an investigation confirmed the presence of the drug was due to a contaminated regulated medicine from Poland, thereby determining that Swiatek was not at fault. Initially provisionally suspended on September 12, she appealed and was able to overturn the suspension on October 4, thus missing three major tournaments: the Korea Open, the China Open, and the Wuhan Open.The established timeline indicated that her period of ineligibility would conclude on December 4, 2024. According to ITIA chief executive Karen Moorhouse, the convergence of factors—especially the nature of the medication and its regulation status—led to Swiatek being categorized with the lowest fault in doping violation assessments. Consequentially, she has forfeited prize money earned at the Cincinnati Open, where she made it to the semi-finals shortly after the positive test. Although the ITIA did not publicly announce the details of Swiatek's provisional suspension due to the swift appeal, the incident highlights the complexities surrounding athlete responsibility when dealing with medications that may vary in regulation across different countries. The ITIA emphasizes that compliance with doping regulations remains critical, regardless of where medications are produced or governed.
